Dr. Bristow
ARCA Biopharma Announces Positive Outcome of End-of-Phase 2 Meeting With FDA on Gencaro Development for Atrial Fibrillation
31 juil. 2018 08h30 HE | ARCA biopharma, Inc.
Single Phase 3 trial may be sufficient for approval of atrial fibrillation indicationPhase 3 clinical trial Special Protocol Assessment submission anticipated 3Q2018Gencaro is in development as...
ARCA Logo - JPEG.jpg
GENETIC-AF Phase 2B Clinical Trial Results Presented in Late Breaking Presentation at European Society of Cardiology Heart Failure 2018 World Congress
29 mai 2018 08h30 HE | ARCA biopharma, Inc.
WESTMINSTER, Colo., May 29, 2018 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...
ARCA Logo - JPEG.jpg
ARCA biopharma Announces Phase 2B GENETIC-AF Clinical Trial Results Selected for Late Breaking Oral Presentation at European Society of Cardiology Heart Failure 2018 World Congress
10 mai 2018 08h30 HE | ARCA biopharma, Inc.
WESTMINSTER, Colo., May 10, 2018 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...
ARCA Logo - JPEG.jpg
ARCA Biopharma announces first quarter 2018 financial results AND Provides Corporate Update
08 mai 2018 16h15 HE | ARCA biopharma, Inc.
WESTMINSTER, Colo., May 08, 2018 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...
Daxor logo thumbnail.png
New Data Showing Patient Care Individualized by Daxor’s Precision Blood Volume Analysis Reduces Heart Failure Readmissions by 56% and Mortality by over 80% Presented at the American College of Cardiology 2018 Annual Scientific Session
14 mars 2018 08h00 HE | Daxor Corporation
(NYSE MKT LLC: DXR) New York, NY, March 14, 2018 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with medical instrumentation and biotechnology operations,...
MyoKardia_Logo_RGB.png
MyoKardia Begins Patient Dosing in Phase 1b Clinical Study of MYK-491 in Dilated Cardiomyopathy Patients
14 févr. 2018 08h30 HE | MyoKardia, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 14, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of...
nuwellis.jpg
CHF Solutions, Inc. to Present at the LD Micro 10th Annual Main Event on December 5, 2017
30 nov. 2017 07h15 HE | CHF Solutions, Inc.
EDEN PRAIRIE, Minn., Nov. 30, 2017 (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (NASDAQ:CHFS) announced today that Claudia Drayton, Chief Financial Officer will be a featured presenter at the LD Micro...
nuwellis.jpg
CHF Solutions, Inc. Announces Pricing of $18.0 Million Underwritten Public Offering
22 nov. 2017 08h30 HE | CHF Solutions, Inc.
EDEN PRAIRIE, Minn., Nov. 22, 2017 (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (NASDAQ:CHFS) announced today the pricing of an underwritten public offering of Series F convertible preferred stock,...
Dr. Bristow
ARCA Biopharma Announces Issuance of European Patent for Treating Cardiovascular Diseases and Conditions With a New Chemical Entity Utilizing Genetic Targeting
16 nov. 2017 08h30 HE | ARCA biopharma, Inc.
WESTMINSTER, Colo., Nov. 16, 2017 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...
nuwellis.jpg
CHF Solutions’ Aquadex FlexFlow® Aquapheresis System Receives FDA IDE Approval for Clinical Study for Pediatric Use
29 juin 2017 07h00 HE | CHF Solutions
EDEN PRAIRIE, Minn., June 29, 2017 (GLOBE NEWSWIRE) -- CHF Solutions, Inc., (fka Sunshine Heart, Inc.) (NASDAQ:CHFS) announced today that researchers in the Stanford University School of Medicine’s...